Elevated serum levels of serum neurofilament light chain (sNfL), a biomarker of neurodegeneration, at diagnosis may be useful as a prognostic marker of survival in ALS.
Why this matters
ALS is a progressive neurodegenerative disease, leading to death in a median time of 3 years after onset. However, prognosis of the disease is highly variable, ranging from a few months to over 30 years. Use of sNfL as biological marker to predict prognosis will help physicians to more accurately inform patients of their survival prognosis, and to better evaluate clinical trial outcomes.